- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02340702
Chronic Obstructive Pulmonary Disease (COPD) in Patients Hospitalized for Acute Decompensated Heart Failure. (COPD)
COPD in Patients Hospitalized for Acute Decompensated Heart Failure.
Studieoversikt
Detaljert beskrivelse
Background:
The prevalence of mild to moderate COPD is ~5%-10% with one-year mortality around 3% while heart failure affects is1%-3% with one year mortality 5-7% in the community. The mortality of COPD and heart failure dramatically increase following hospitalization.
Heart failure and COPD are independent predictors of increased morbidity and mortality. COPD and heart failure frequently co-exist in an individual patient through the shared risk factors. The prevalence of COPD in heart failure patient-population and vice verse varies widely according to patient-selection and age of the population. Estimates suggest that COPD is present in 10-40% of the patients with heart failure. Conversely, unrecognized heart failure is identified in approximately 20% of the patient with COPD. The impact of COPD on clinical outcome in patients with acute decompensated heart failure is unclear.
Methods:
This is an observational cohort study. Per national registry, acute heart failure is defined as either new onset heart failure or decompensation of chronic established heart failure with symptoms sufficient to warrant hospitalization.
The data related to the following variables would be collected:
age, gender, severity of heart failure (mild, moderate, and severe prior to admission), presence of dyspnea, peripheral edema, crackles, systolic and diastolic blood pressure (on admission and on discharge), heart rate (on admission and on discharge), oxygen saturation (on admission and discharge), blood urea nitrogen (on admission and discharge), serum creatinine (on admission and discharge), serum sodium (on admission and discharge), hemoglobin (on admission and discharge), red cell distribution width (on admission and discharge), electrocardiographic intervals (on admission and discharge), comorbidities (coronary artery disease, chronic kidney disease, atrial fibrillation, diabetes, hypertension, dyslipidemia, peripheral artery disease, COPD/asthma, left ventricular ejection fraction >40%. Medication use: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, aspirin, metoprolol tartrate, metoprolol succinate, carvedilol, atenolol, amlodipine, Cardizem, clopidogrel, digoxin, diuretics, statins, nitrates, warfarin, non-steroidal anti-inflammatory drugs, hydralazine.
End-points:
1) All cause in-hospital death and 2) length of hospital stay between heart failure patients with COPD and those with no COPD.
Studietype
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Heart failure
Exclusion Criteria:
- Ambulatory patients
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Patient with COPD and those without COPD
The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
|
COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of <0.7.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
In-hospital mortality
Tidsramme: Average of 5-weeks
|
Participants would be followed for the duration of hospital stay
|
Average of 5-weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Length of hospital stay
Tidsramme: Average of 5-weeks
|
Average of 5-weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 14-006196
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på COPD
-
University of ChicagoCOPD Foundation; Society of Hospital Medicine; Onda Collective; The Hospital...RekrutteringKOLS | KOLS-eksaserbasjon akuttForente stater
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)RekrutteringKOLS (kronisk obstruktiv lungesykdom)Forente stater
-
Boston Scientific CorporationPneumRx, Inc.AvsluttetKOLS-symptomer etter spiralprosedyreSveits
-
Universitair Ziekenhuis BrusselFullførtAstma | Overholdelse, medisinering | KOLSBelgia
-
Wake Forest University Health SciencesRekrutteringIkke-småcellet lungekreft stadium III | Uopererbart ikke-småcellet lungekarsinomForente stater
-
Spyridon FortisAmerican Thoracic SocietyRekruttering
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RekrutteringIkke-småcellet lungekreft | YtelsesstatusForente stater
-
St. Jude Children's Research HospitalAktiv, ikke rekrutterende